/
•
•
Detailed stories on technology startups, business and economic current affairs.
The diagnostics firm was acquired at great cost, but is unable to support PharmEasy’s core online pharmacy business.

Just a few months ago, it looked like PharmEasy was well on the way to listing on the public markets at a valuation of over $5 billion.
But with investors fast losing their appetite for technology stocks in recent months, the online drugs and medical services startup shelved its IPO in November. Now, some of the decisions it took in the run-up to the withdrawn public offer are beginning to bite. In particular, its acquisition of diagnostics chain Thyrocare in June 2021, which has become a millstone around its neck, threatening to thwart PharmEasy’s ambition to build India’s biggest …